CJEU rules out SPCs for new drug formulations, but leaves uncertainty over therapeutic uses
Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.